Market Cap
$133.5B
VRTX
VERTEX PHARMACEUTICALS INC / MA
$503.60 ▼ -0.62%
Prev close $506.74Market cap$133.5B
ConsensusStrong Buy
12-mo target$571.39 (+13.5%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)32 New Institutional Positions18 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on VRTX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$97.4B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $16.5M sell
Insider Net $
-$16.5M
Social Sentiment
50° Neutral
SEC Reports
11
Congressional
3 trades
Price chart 30d -9.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Nov 30, 2026 fda_pdufa
PDUFA: VRTX — povetacicept in IgA nephropathy (IgAN) — 2026-11-30
FDA target action date 2026-11-30 for VRTX (VERTEX PHARMACEUTICALS INC / MA). Drug: povetacicept. In
Sep 8, 2026 Insider
van Grunsven Jasper was granted 8,682 shares
EVP, CP and NPPO
Aug 28, 2026 Insider
Ambrose Kristen was granted 5,000 shares
SVP & Chief Accounting Officer
Aug 27, 2026 Insider
SACHS BRUCE I gifted 6,000 shares
Director
Aug 26, 2026 Congress
David Taylor sell
$1,001 - $15,000 — House
Aug 14, 2026 Event
Jul 8, 2026 SEC HSR Early Termination: Vertex Pharmaceuticals Incorporated; Crinetics Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Vertex P
Three Vertex EVPs sold a total of $1.49M in stock over a one-week period ending July 2, 2026, representing less than 0.0
CLUSTER — Impact 2/10
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cas
8-K — Impact 7/10
Analyst ratings buy % +26.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 36 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 4, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Aug 4, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Jul 13, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 13, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 7, 2026 | Baird | MAINTAIN | Underperform | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 11 | 18 | 6 | 0 | 1 | 81% | |
| Aug 1, 2026 | 11 | 19 | 6 | 0 | 1 | 81% | |
| Jul 1, 2026 | 13 | 20 | 6 | 0 | 1 | 83% | |
| Jun 1, 2026 | 13 | 20 | 6 | 0 | 1 | 83% | |
| May 1, 2026 | 13 | 19 | 6 | 0 | 1 | 82% | |
| Apr 1, 2026 | 13 | 20 | 6 | 0 | 1 | 83% | |
| Mar 1, 2026 | 12 | 19 | 7 | 0 | 1 | 79% | |
| Feb 1, 2026 | 11 | 19 | 8 | 0 | 1 | 77% |
Price targets
Where 28 covering analysts think VRTX trades over the next 12 months.
$571.39 +13.5% upside Buy
Current$503.60 Low$350.00 Median$577.50 High$672.00 28 analysts
$350.00$672.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 9 neutral · avg impact 3.5/10.
NEUTRALCLUSTER2/10
Three Vertex EVPs sold a total of $1.49M in stock over a one-week period ending July 2, 2026, repres
Jul 8, 2026
BULLISH8-K7/10
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85
Jul 7, 2026
NEUTRALCLUSTER2/10
Two VRTX C-suite executives (CMO and Chief Legal Officer) sold a combined ~$704K in open-market sale
Jul 7, 2026
NEUTRALCLUSTER2/10
Two senior executives at Vertex Pharmaceuticals (EVP/CMO and EVP/Chief Legal Officer) sold a combine
Jun 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Nov 30, 2026
fda_pdufa
PDUFA: VRTX — povetacicept in IgA nephropathy (IgAN) — 2026-11-30
FDA target action date 2026-11-30 for VRTX (VERTEX PHARMACEUTICALS INC / MA). Drug: povetacicept. Indication: IgA nephropathy (IgAN). U.S. FDA assigne
Sep 22, 2026
short_volume
Short Volume: VRTX — 57.3% short (0.3M / 0.5M)
Short: 286,721 | Exempt: 691 | TRF Vol: 500,285 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
Clinical Trial
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Phase Phase 3 — COMPLETED
Sep 14, 2026
Clinical Trial
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
Phase Phase 2 — COMPLETED
Sep 14, 2026
clinical_trial_readout
Results Pending: Povetacicept (Phase 2) — Completed 33d ago
Trial: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Ve
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.22 | $-29.56–$5.06 | -125.4% | -124.8% | 5↑ 7↓ | $3.4B | 12 |
| Next Q | $4.56 | $4.04–$5.05 | -9.3% | -7.6% | 3↑ 8↓ | $3.5B | 13 |
| Current FY | $16.17 | $-2.72–$19.31 | -12.1% | -15.1% | 5↑ 7↓ | $13.2B | 15 |
| Next FY | $20.11 | $17.70–$22.89 | 24.3% | -8.6% | 8↑ 5↓ | $14.6B | 15 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.220 | — |
| 7d ago | $-1.737 | +0.517 |
| 30d ago | $4.920 | -6.139 |
| 60d ago | $4.907 | -6.127 |
| 90d ago | $4.950 | -6.170 |
Institutional ownership
Which big funds own VRTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $97.4B total value (196,339,445 shares) as of 2026-Q2. Top holders: Capital, BlackRock,, Capital. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Capital World Investors | 26,115,014 | $13.0B | 13.3% | — |
| BlackRock, Inc. | 24,109,373 | $12.0B | 12.3% | — |
| Capital Research Global Investors | 19,490,637 | $9.7B | 9.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 16,580,713 | $8.2B | 8.5% | — |
| STATE STREET CORP | 11,871,459 | $5.9B | 6.1% | — |
| Invesco Ltd. | 8,043,052 | $4.0B | 4.1% | — |
| JPMORGAN CHASE & CO | 6,517,600 | $3.3B | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 6,017,848 | $3.0B | 3.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,878,987 | $2.4B | 2.5% | — |
| Capital International Investors | 4,695,144 | $2.3B | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,971,681 | — | $1.5B |
| FMR LLC | TRIM | 2,020,265 | 1,457,158 | -27.9% | $723.8M |
| Assenagon Asset Management S.A. | ADD | 537,248 | 759,564 | +41.4% | $377.3M |
| AMERICAN CENTURY COMPANIES INC | TRIM | 813,285 | 580,901 | -28.6% | $288.6M |
| RAYMOND JAMES FINANCIAL INC | ADD | 444,496 | 556,876 | +25.3% | $276.6M |
| MARSHALL WACE, LLP | ADD | 317,058 | 543,897 | +71.5% | $270.2M |
| Pictet Asset Management Holding SA | ADD | 337,569 | 539,255 | +59.7% | $268.3M |
| CITADEL ADVISORS LLC | ADD | 339,298 | 510,430 | +50.4% | $253.5M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 30,823 | 468,410 | +1419.7% | $232.7M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | 327,498 | 423,049 | +29.2% | $214.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$16.5M — $0.00 bought, $16.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | van Grunsven Jasper | EVP, CP and NPPO | AWARD | 8,682 | — | — |
| Aug 28, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | AWARD | 5,000 | — | — |
| Aug 27, 2026 | SACHS BRUCE I | Director | GIFT | 6,000 | — | — |
| Jul 21, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | AWARD | 8,251 | — | — |
| Jul 21, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | AWARD | 8,251 | — | — |
| Jul 15, 2026 | Garber Alan M | Director | AWARD | 31.56 | $475.28 | $15.0K |
| Jul 15, 2026 | SACHS BRUCE I | Director | AWARD | 99.941 | $475.28 | $47.5K |
| Jul 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | SELL | 1,541 | $519.00 | $799.8K |
| Jul 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | SELL | 1,500 | $524.99 | $787.5K |
| Jul 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | 828 | $502.71 | $416.2K |
Congressional trades
VRTX trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Vertex Pharmaceuticals Inc | Sep 7, 2026(13d) |
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Vertex Pharmaceuticals Inc | May 13, 2026(31d) |
| Mar 27, 2026 | Alan Armstrong | R | SENATE | BUY | $1,001 - $15,000 | Vertex Pharmaceuticals Inc | Jul 22, 2026(117d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VRTX.
Shares short
4,716,867
Settlement Sep 15, 2026
Change vs prior
+1.2%
Semi-monthly cycle
Days to cover
5.0
At avg daily volume
Of shares outstanding
≈1.9%
Estimate — not % of float
All VRTX filing & press-release reports (11)
- CLUSTER reportJul 8, 2026
- 8-K reportJul 7, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMar 17, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 26, 2026